Speed at rest.

We engineer proteins that turn fragile biologics into a stable glass — no refrigeration, no cold chain. Add water, and they spring back to life.

See how it works →The platform
Company overview →

Protein design · Molecular vitrification · Ambient-stable biologics

drag to dry →
Hydrated · in motionVitrified · at rest

01 - THE PROBLEM

A third of modern medicine cannot survive a warm afternoon.

~50%
of the world's vaccine doses are wasted before they reach a patient, from all causes, not cold-chain failures alone.
WHO
$35B+ / yr
of product lost to cold-chain failures every year, close to 10% of the value of all medicine that must stay cold.
Industry estimate, 2024
$22B / yr
spent every year just to keep biologics cold, guarding the $384 billion of pharmaceutical value that cannot survive a warm room.
Industry estimate, 2024 · IQVIA, 2023

We still ship medicine on ice.

Every biologic has a temperature range it must never leave. Green means the dose is safe. Red means it left the range, too warm or cold, either spoil it. Pick a temperature range, follow one dose from the factory to a patient, click any stop, then flip the switch.

Refrigerated
FactoryAir freightCustomsCold storeLast mileHealth postPatient
In range, safe
Out of range, too warm or frozen

Go deeper on the cold chain →

The medicines you know are all on the cold chain.

The world's biggest drugs, and the shots in your arm, every one has to stay cold to work. Flip the switch to see what that costs, and what a proven reformulation could give back.

Cold logistics run about 5% of a biologic's sales. Reformulate it to survive at room temperature and that cost can be roughly halved — across the medicines below, on the order of $3.1B a year that never has to be spent keeping them cold.

Modeled from FY2024 company revenue and the industry's ~5% cold-chain logistics rate, at a 50% reduction.

$124B
a year in medicines you recognize, every one of them cold.
$124B in annual sales, about $6.2B a year in cold logistics, halved: about $3.1B a year.
Storage conditions are FDA-labeled. Click any medicine for its exact condition and source.

Every medicine here is cold-chain by its FDA label. Revenue figures are FY2024, from company filings. Still Velocity's own performance is under validation.

02 - The Insight

Nature produced a proof of concept. We are engineering it for modern medicine.

Tardigrade micrograph


Why now

01
AI-driven protein design has matured enough to engineer entirely new sequences from first principles.
02
Tooling built specifically for intrinsically disordered proteins now exists — the exact class this depends on.
03
Cold-chain losses keep climbing as biologics take over the pipeline. The problem is getting bigger, not smaller.

Tardigrades and other organisms survive total drying using disordered proteins that vitrify into a protective glass. We design synthetic analogs of that biology — on purpose, and on demand.

Go deeper on nature's proof →

03 - How It Works

Vitrification: locking life into a glass.

We engineer proteins that do on command what tardigrades do to survive drying — self-assembling into a fibrous mesh, then a stable glass that locks a payload safe, and releasing it intact when water returns.

HYDRATED

01 — Disordered

In water, our engineered proteins stay intrinsically disordered — loose, flexible strands. The payload they will protect floats free, vulnerable to heat and time.

Go deeper on vitrification →

04 - The Platform

Proteins nature never made.

We engineer entirely new proteins from the ground up, topology first, grounded in the biology tardigrades use to survive drying. A platform, not a molecule.

10
provisional patents filed to date, protecting the engineered library and its methods.
3,700+
novel protein sequences designed from the ground up.
2,985
candidates evaluated through the in-silico pipeline.

The pipeline (select a stage to see the process and where we are)

Design

We engineer entirely new protein sequences from the ground up, topology first, rather than copying nature.

What's novel

De-novo, not derived. The novel set sits below 15% identity to any known protein, with topology nature never made, grounded in the biology tardigrades use to survive drying.

Status
Complete
Detail
Novel sequence library built.

05 - Team

The people and partners building this.

A founding team that spans protein science, enterprise operations, and frontline medicine, building alongside world-class compute, a leading academic lab in tardigrade protein science, and a forming advisory bench.

Founders

Tim O'Brien
Tim O'Brien
Co-Founder & CEO
University of Pittsburgh, B.S. Biology and B.A. Finance · MBA, Columbia
  • VP of Finance and Head of M&A at Vytalize Health, ranked #1 on the 2024 Inc. 5000
  • Background in healthcare corporate development, M&A, and growth finance
  • Over 12 years in investment banking, private equity, and M&A before founding Still Velocity
Jackson Reimers
Jackson Reimers
Co-Founder & COO
University of Pittsburgh, B.S. Finance · MBA, Johns Hopkins
  • Product manager in data and AI at IBM, bridging the gap between product and sales
  • Led enterprise go-to-market and strategic accounts at DataStax
  • Background across AI infrastructure and enterprise software
Chas Elliott
Co-Founder & CMO
University of Pittsburgh, B.S. Biology · MD, Case Western Reserve
  • Attending emergency medicine physician at the University of Arizona
  • Serves on a health-system pharmacy and therapeutics (formulary) committee
  • Sees the downstream cost of failed and expired medicines firsthand in the emergency department

Building with

Programs
NSF
Invited by the NSF SBIR/STTR program, America's Seed Fund, to submit a full Phase I proposal. NSF screens Project Pitches for technical innovation, risk, and commercial and societal impact.
NVIDIA Inception
Member of NVIDIA's Inception program, with access to resources and tooling for high-throughput molecular simulation.
Validation
Leading Academic Lab
Experimental validation runs under a signed sponsored research agreement with one of the few academic groups worldwide working directly on tardigrade protein stabilization. The lab is federally funded, and its peer-reviewed work demonstrated that these proteins can hold a biologic stable through drying.
Guidance
Advisors
Developing a scientific and go-to-market advisory bench spanning biologics development, preservation science, IP licensing, and commercial translation. Backgrounds include decades of pharmaceutical bioprocess leadership and NIH-funded academic research.

06 - Get Involved

Where do you fit in?

Partners

License the sequences or explore a co-development collaboration.

License or collaborate →

Investors

A capital-light IP-licensing company with early traction and a broad platform.

Get in touch →

Careers

Protein design, molecular simulation, and the people to build it all.

Join us →

Advisors

Scientific, regulatory, and commercial advisors shaping the platform's direction.

Advisory inquiry →